287 related articles for article (PubMed ID: 25355728)
1. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.
Peterfy C; Emery P; Tak PP; Østergaard M; DiCarlo J; Otsa K; Navarro Sarabia F; Pavelka K; Bagnard MA; Gylvin LH; Bernasconi C; Gabriele A
Ann Rheum Dis; 2016 Jan; 75(1):170-7. PubMed ID: 25355728
[TBL] [Abstract][Full Text] [Related]
2. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients.
Østergaard M; Emery P; Conaghan PG; Fleischmann R; Hsia EC; Xu W; Rahman MU
Arthritis Rheum; 2011 Dec; 63(12):3712-22. PubMed ID: 22127693
[TBL] [Abstract][Full Text] [Related]
3. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
Conaghan PG; Peterfy C; Olech E; Kaine J; Ridley D; Dicarlo J; Friedman J; Devenport J; Troum O
Ann Rheum Dis; 2014 May; 73(5):810-6. PubMed ID: 24525910
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).
Emery P; Deodhar A; Rigby WF; Isaacs JD; Combe B; Racewicz AJ; Latinis K; Abud-Mendoza C; Szczepanski LJ; Roschmann RA; Chen A; Armstrong GK; Douglass W; Tyrrell H
Ann Rheum Dis; 2010 Sep; 69(9):1629-35. PubMed ID: 20488885
[TBL] [Abstract][Full Text] [Related]
5. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
Tak PP; Rigby W; Rubbert-Roth A; Peterfy C; van Vollenhoven RF; Stohl W; Healy E; Hessey E; Reynard M; Shaw T
Ann Rheum Dis; 2012 Mar; 71(3):351-7. PubMed ID: 22012969
[TBL] [Abstract][Full Text] [Related]
6. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
Axelsen MB; Eshed I; Hørslev-Petersen K; Stengaard-Pedersen K; Hetland ML; Møller J; Junker P; Pødenphant J; Schlemmer A; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Krogh NS; Johansen JS; Østergaard M;
Ann Rheum Dis; 2015 May; 74(5):867-75. PubMed ID: 24412895
[TBL] [Abstract][Full Text] [Related]
7. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
[TBL] [Abstract][Full Text] [Related]
8. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.
Keystone E; Emery P; Peterfy CG; Tak PP; Cohen S; Genovese MC; Dougados M; Burmester GR; Greenwald M; Kvien TK; Williams S; Hagerty D; Cravets MW; Shaw T
Ann Rheum Dis; 2009 Feb; 68(2):216-21. PubMed ID: 18388156
[TBL] [Abstract][Full Text] [Related]
9. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
Conaghan PG; Durez P; Alten RE; Burmester GR; Tak PP; Klareskog L; Catrina AI; DiCarlo J; Gaillez C; Le Bars M; Zhou X; Peterfy C
Ann Rheum Dis; 2013 Aug; 72(8):1287-94. PubMed ID: 22915624
[TBL] [Abstract][Full Text] [Related]
10. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate.
Cohen SB; Keystone E; Genovese MC; Emery P; Peterfy C; Tak PP; Cravets M; Shaw T; Hagerty D
Ann Rheum Dis; 2010 Jun; 69(6):1158-61. PubMed ID: 20439295
[TBL] [Abstract][Full Text] [Related]
11. Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932).
Peterfy CG; Olech E; DiCarlo JC; Merrill JT; Countryman PJ; Gaylis NB
Arthritis Res Ther; 2013 Mar; 15(2):R44. PubMed ID: 23514433
[TBL] [Abstract][Full Text] [Related]
12. Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial.
Ahmad HA; Baker JF; Østergaard M; Ye J; Emery P; Conaghan PG
Adv Ther; 2019 Sep; 36(9):2384-2393. PubMed ID: 31278695
[TBL] [Abstract][Full Text] [Related]
13. Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy.
Peterfy C; Kremer J; Rigby W; Singer N; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
J Rheumatol; 2020 Mar; 47(3):325-332. PubMed ID: 31154414
[TBL] [Abstract][Full Text] [Related]
14. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoring.
Beals C; Baumgartner R; Peterfy C; Balanescu A; Mirea G; Harabagiu A; Popa S; Cheng A; Feng D; Ashton E; DiCarlo J; Vallee MH; Dardzinski BJ
PLoS One; 2017; 12(12):e0187397. PubMed ID: 29236711
[TBL] [Abstract][Full Text] [Related]
16. MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
Peterfy C; DiCarlo J; Emery P; Genovese MC; Keystone EC; Taylor PC; Schlichting DE; Beattie SD; Luchi M; Macias W
J Rheumatol; 2019 Aug; 46(8):887-895. PubMed ID: 30647190
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
[TBL] [Abstract][Full Text] [Related]
18. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
19. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial.
Conaghan PG; Emery P; Østergaard M; Keystone EC; Genovese MC; Hsia EC; Xu W; Rahman MU
Ann Rheum Dis; 2011 Nov; 70(11):1968-74. PubMed ID: 21784729
[TBL] [Abstract][Full Text] [Related]
20. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16.
Østergaard M; Jacobsson LT; Schaufelberger C; Hansen MS; Bijlsma JW; Dudek A; Rell-Bakalarska M; Staelens F; Haake R; Sundman-Engberg B; Bliddal H
Ann Rheum Dis; 2015 Jun; 74(6):1156-63. PubMed ID: 25512675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
